data_1edw_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 1edw _Structure_validation_residue.Date_analyzed 2016-10-06 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig full ' A' A ' 1' ' ' TYR . . . . . . . . . . . . . 14.3 t80 . . . . . 0 N--CA 1.473 0.714 0 N-CA-C 108.361 -0.977 . . . . 0.62 108.361 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . 58.06 -105.56 0.26 Allowed 'General case' 0 CA--C 1.532 0.256 0 C-N-CA 125.051 1.34 . . . . 0.62 110.303 -179.808 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -65.37 -49.6 60.18 Favored Glycine 0 CA--C 1.527 0.838 0 N-CA-C 109.913 -1.275 . . . . 0.62 109.913 173.323 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 21.6 t -82.98 65.04 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.247 0 N-CA-C 107.086 -1.45 . . . . 0.62 107.086 -179.152 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -123.75 -170.89 2.21 Favored 'General case' 0 CA--C 1.53 0.196 0 C-N-CA 125.404 1.482 . . . . 0.62 109.676 -178.37 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 88.8 t80 -31.85 -44.2 0.08 Allowed 'General case' 0 N--CA 1.466 0.352 0 C-N-CA 127.161 2.185 . . . . 0.62 114.931 -171.67 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 86.8 t80 -39.82 -48.79 2.31 Favored 'General case' 0 CA--C 1.535 0.387 0 C-N-CA 124.758 1.223 . . . . 0.62 112.815 175.258 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 3.8 tp -83.92 -153.74 0.04 OUTLIER 'Isoleucine or valine' 0 CA--C 1.54 0.584 0 C-N-CA 123.383 0.673 . . . . 0.62 109.548 -176.397 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 10.5 m-85 61.86 7.54 2.07 Favored 'General case' 0 CA--C 1.534 0.355 0 O-C-N 120.852 -1.155 . . . . 0.62 112.961 178.305 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 7.0 m 34.04 43.0 0.06 Allowed 'General case' 0 CA--C 1.539 0.52 0 C-N-CA 124.627 1.171 . . . . 0.62 111.07 -156.055 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' HIS . . . . . . . . . . . . . 6.5 m-70 54.87 17.14 1.68 Allowed 'General case' 0 CA--C 1.543 0.675 0 N-CA-C 114.777 1.399 . . . . 0.62 114.777 -179.803 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -114.4 -166.92 1.15 Allowed 'General case' 0 CA--C 1.533 0.312 0 CA-C-N 119.843 1.202 . . . . 0.68000000000000005 110.121 176.311 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -72.3 35.69 0.66 Allowed Glycine 0 CA--C 1.534 1.222 0 C-N-CA 124.791 1.186 . . . . 0.62 115.765 -169.636 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.1 t 66.59 35.13 5.53 Favored 'General case' 0 CA--C 1.537 0.458 0 CA-C-N 118.256 1.028 . . . . 0.62 112.303 165.887 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 24.2 p-10 -154.76 -71.32 0.13 Allowed 'General case' 0 CA--C 1.535 0.399 0 N-CA-C 112.76 0.652 . . . . 0.70999999999999996 112.76 -174.353 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' PHE . . . . . . . . . . . . . 54.6 t80 -104.85 82.71 1.91 Allowed 'General case' 0 N--CA 1.452 -0.327 0 C-N-CA 125.941 1.696 . . . . 0.62 108.339 -167.718 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 166.08 -59.04 0.24 Allowed Glycine 0 CA--C 1.526 0.733 0 N-CA-C 110.632 -0.987 . . . . 0.62 110.632 -168.088 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 66.9 Cg_endo -78.66 55.4 5.49 Favored 'Trans proline' 0 N--CA 1.458 -0.569 0 C-N-CA 123.188 2.592 . . . . 0.53000000000000003 109.875 177.147 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . 0.268 0.5 OUTLIER 64.25 -58.62 0.21 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.545 0 C-N-CA 127.011 2.124 . . . . 0.62 112.837 -173.584 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 87.4 t80 -168.65 166.22 11.89 Favored 'General case' 0 N--CA 1.454 -0.249 0 C-N-CA 125.339 1.456 . . . . 0.62 107.707 -177.94 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' MET . . . . . . . . . . . . . 23.1 ptt? -72.15 64.0 0.53 Allowed 'General case' 0 CA--C 1.54 0.577 0 C-N-CA 124.88 1.272 . . . . 0.73999999999999999 112.782 -178.719 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 9.8 t -134.68 -56.64 0.83 Allowed 'General case' 0 CA--C 1.537 0.475 0 C-N-CA 125.461 1.504 . . . . 0.62 108.762 163.164 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 43.9 mm -44.9 -46.63 28.89 Favored Pre-proline 0 CA--C 1.543 0.696 0 C-N-CA 124.601 1.16 . . . . 0.62 113.964 174.461 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_endo -65.88 -23.78 54.49 Favored 'Trans proline' 0 N--CA 1.455 -0.757 0 C-N-CA 121.639 1.559 . . . . 0.53000000000000003 113.089 -179.858 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -76.04 -48.76 19.67 Favored 'General case' 0 C--N 1.34 0.186 0 N-CA-C 108.323 -0.992 . . . . 0.62 108.323 169.054 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 1.9 t80 . . . . . 0 C--O 1.252 1.194 0 C-N-CA 125.352 1.461 . . . . 0.52000000000000002 109.134 178.351 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' TYR . . . . . . . . . . . . . 14.3 t80 . . . . . 0 N--CA 1.473 0.714 0 N-CA-C 108.361 -0.977 . . . . 0.62 108.361 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . 58.06 -105.56 0.26 Allowed 'General case' 0 CA--C 1.532 0.256 0 C-N-CA 125.051 1.34 . . . . 0.62 110.303 -179.808 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -65.37 -49.6 60.18 Favored Glycine 0 CA--C 1.527 0.838 0 N-CA-C 109.913 -1.275 . . . . 0.62 109.913 173.323 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 21.6 t -82.98 65.04 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.247 0 N-CA-C 107.086 -1.45 . . . . 0.62 107.086 -179.152 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -123.75 -170.89 2.21 Favored 'General case' 0 CA--C 1.53 0.196 0 C-N-CA 125.404 1.482 . . . . 0.62 109.676 -178.37 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 88.8 t80 -31.85 -44.2 0.08 Allowed 'General case' 0 N--CA 1.466 0.352 0 C-N-CA 127.161 2.185 . . . . 0.62 114.931 -171.67 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 86.8 t80 -39.82 -48.79 2.31 Favored 'General case' 0 CA--C 1.535 0.387 0 C-N-CA 124.758 1.223 . . . . 0.62 112.815 175.258 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 3.8 tp -83.92 -153.74 0.04 OUTLIER 'Isoleucine or valine' 0 CA--C 1.54 0.584 0 C-N-CA 123.383 0.673 . . . . 0.62 109.548 -176.397 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 10.5 m-85 61.86 7.54 2.07 Favored 'General case' 0 CA--C 1.534 0.355 0 O-C-N 120.852 -1.155 . . . . 0.62 112.961 178.305 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 7.0 m 34.04 43.0 0.06 Allowed 'General case' 0 CA--C 1.539 0.52 0 C-N-CA 124.627 1.171 . . . . 0.62 111.07 -156.055 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' HIS . . . . . . . . . . . . . 6.5 m-70 54.87 17.14 1.68 Allowed 'General case' 0 CA--C 1.543 0.675 0 N-CA-C 114.777 1.399 . . . . 0.62 114.777 -179.803 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -114.4 -166.92 1.15 Allowed 'General case' 0 CA--C 1.533 0.312 0 CA-C-N 119.843 1.202 . . . . 0.68 110.121 176.311 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -72.3 35.69 0.66 Allowed Glycine 0 CA--C 1.534 1.222 0 C-N-CA 124.791 1.186 . . . . 0.62 115.765 -169.636 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.1 t 66.59 35.13 5.53 Favored 'General case' 0 CA--C 1.537 0.458 0 CA-C-N 118.256 1.028 . . . . 0.62 112.303 165.887 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 24.2 p-10 -154.76 -71.32 0.13 Allowed 'General case' 0 CA--C 1.535 0.399 0 N-CA-C 112.76 0.652 . . . . 0.71 112.76 -174.353 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' PHE . . . . . . . . . . . . . 54.6 t80 -104.85 82.71 1.91 Allowed 'General case' 0 N--CA 1.452 -0.327 0 C-N-CA 125.941 1.696 . . . . 0.62 108.339 -167.718 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 166.08 -59.04 0.24 Allowed Glycine 0 CA--C 1.526 0.733 0 N-CA-C 110.632 -0.987 . . . . 0.62 110.632 -168.088 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 66.9 Cg_endo -78.66 55.4 5.49 Favored 'Trans proline' 0 N--CA 1.458 -0.569 0 C-N-CA 123.188 2.592 . . . . 0.53 109.875 177.147 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . 0.268 0.5 OUTLIER 64.25 -58.62 0.21 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.545 0 C-N-CA 127.011 2.124 . . . . 0.62 112.837 -173.584 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 87.4 t80 -168.65 166.22 11.89 Favored 'General case' 0 N--CA 1.454 -0.249 0 C-N-CA 125.339 1.456 . . . . 0.62 107.707 -177.94 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 21' ' ' MET . . . . . . . . . . . . . 23.1 ptt? -72.15 64.0 0.53 Allowed 'General case' 0 CA--C 1.54 0.577 0 C-N-CA 124.88 1.272 . . . . 0.74 112.782 -178.719 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 9.8 t -134.68 -56.64 0.83 Allowed 'General case' 0 CA--C 1.537 0.475 0 C-N-CA 125.461 1.504 . . . . 0.62 108.762 163.164 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 43.9 mm -44.9 -46.63 28.89 Favored Pre-proline 0 CA--C 1.543 0.696 0 C-N-CA 124.601 1.16 . . . . 0.62 113.964 174.461 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_endo -65.88 -23.78 54.49 Favored 'Trans proline' 0 N--CA 1.455 -0.757 0 C-N-CA 121.639 1.559 . . . . 0.53 113.089 -179.858 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -76.04 -48.76 19.67 Favored 'General case' 0 C--N 1.34 0.186 0 N-CA-C 108.323 -0.992 . . . . 0.62 108.323 169.054 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 1.9 t80 . . . . . 0 C--O 1.252 1.194 0 C-N-CA 125.352 1.461 . . . . 0.52 109.134 178.351 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' TYR . . . . . . . . . . . . . 14.3 t80 . . . . . 0 N--CA 1.473 0.714 0 N-CA-C 108.361 -0.977 . . . . 0.62 108.361 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . 58.06 -105.56 0.26 Allowed 'General case' 0 CA--C 1.532 0.256 0 C-N-CA 125.051 1.34 . . . . 0.62 110.303 -179.808 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -65.37 -49.6 60.18 Favored Glycine 0 CA--C 1.527 0.838 0 N-CA-C 109.913 -1.275 . . . . 0.62 109.913 173.323 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 21.6 t -82.98 65.04 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.247 0 N-CA-C 107.086 -1.45 . . . . 0.62 107.086 -179.152 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -123.75 -170.89 2.21 Favored 'General case' 0 CA--C 1.53 0.196 0 C-N-CA 125.404 1.482 . . . . 0.62 109.676 -178.37 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 88.8 t80 -31.85 -44.2 0.08 Allowed 'General case' 0 N--CA 1.466 0.352 0 C-N-CA 127.161 2.185 . . . . 0.62 114.931 -171.67 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 86.8 t80 -39.82 -48.79 2.31 Favored 'General case' 0 CA--C 1.535 0.387 0 C-N-CA 124.758 1.223 . . . . 0.62 112.815 175.258 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 3.8 tp -83.92 -153.74 0.04 OUTLIER 'Isoleucine or valine' 0 CA--C 1.54 0.584 0 C-N-CA 123.383 0.673 . . . . 0.62 109.548 -176.397 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 10.5 m-85 61.86 7.54 2.07 Favored 'General case' 0 CA--C 1.534 0.355 0 O-C-N 120.852 -1.155 . . . . 0.62 112.961 178.305 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 7.0 m 34.04 43.0 0.06 Allowed 'General case' 0 CA--C 1.539 0.52 0 C-N-CA 124.627 1.171 . . . . 0.62 111.07 -156.055 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' HIS . . . . . . . . . . . . . 6.5 m-70 54.87 17.14 1.68 Allowed 'General case' 0 CA--C 1.543 0.675 0 N-CA-C 114.777 1.399 . . . . 0.62 114.777 -179.803 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -114.4 -166.92 1.15 Allowed 'General case' 0 CA--C 1.533 0.312 0 CA-C-N 119.843 1.202 . . . . 0.68 110.121 176.311 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -72.3 35.69 0.66 Allowed Glycine 0 CA--C 1.534 1.222 0 C-N-CA 124.791 1.186 . . . . 0.62 115.765 -169.636 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.1 t 66.59 35.13 5.53 Favored 'General case' 0 CA--C 1.537 0.458 0 CA-C-N 118.256 1.028 . . . . 0.62 112.303 165.887 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 24.2 p-10 -154.76 -71.32 0.13 Allowed 'General case' 0 CA--C 1.535 0.399 0 N-CA-C 112.76 0.652 . . . . 0.71 112.76 -174.353 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' PHE . . . . . . . . . . . . . 54.6 t80 -104.85 82.71 1.91 Allowed 'General case' 0 N--CA 1.452 -0.327 0 C-N-CA 125.941 1.696 . . . . 0.62 108.339 -167.718 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 166.08 -59.04 0.24 Allowed Glycine 0 CA--C 1.526 0.733 0 N-CA-C 110.632 -0.987 . . . . 0.62 110.632 -168.088 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 66.9 Cg_endo -78.66 55.4 5.49 Favored 'Trans proline' 0 N--CA 1.458 -0.569 0 C-N-CA 123.188 2.592 . . . . 0.53 109.875 177.147 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . 0.268 0.5 OUTLIER 64.25 -58.62 0.21 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.545 0 C-N-CA 127.011 2.124 . . . . 0.62 112.837 -173.584 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 87.4 t80 -168.65 166.22 11.89 Favored 'General case' 0 N--CA 1.454 -0.249 0 C-N-CA 125.339 1.456 . . . . 0.62 107.707 -177.94 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' MET . . . . . . . . . . . . . 23.1 ptt? -72.15 64.0 0.53 Allowed 'General case' 0 CA--C 1.54 0.577 0 C-N-CA 124.88 1.272 . . . . 0.74 112.782 -178.719 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 9.8 t -134.68 -56.64 0.83 Allowed 'General case' 0 CA--C 1.537 0.475 0 C-N-CA 125.461 1.504 . . . . 0.62 108.762 163.164 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 43.9 mm -44.9 -46.63 28.89 Favored Pre-proline 0 CA--C 1.543 0.696 0 C-N-CA 124.601 1.16 . . . . 0.62 113.964 174.461 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_endo -65.88 -23.78 54.49 Favored 'Trans proline' 0 N--CA 1.455 -0.757 0 C-N-CA 121.639 1.559 . . . . 0.53 113.089 -179.858 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -76.04 -48.76 19.67 Favored 'General case' 0 C--N 1.34 0.186 0 N-CA-C 108.323 -0.992 . . . . 0.62 108.323 169.054 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 1.9 t80 . . . . . 0 C--O 1.252 1.194 0 C-N-CA 125.352 1.461 . . . . 0.52 109.134 178.351 . . . . . . . . 0 0 . 1 stop_ save_